Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Buntanetap - Annovis Bio

Next Previous
Drug Profile

Buntanetap - Annovis Bio

Alternative Names: (+)-(3aR)-phenserine; (+)-phenserine; ANVS-401; ANVS-405; ANVS402; Buntanetap tartrate; Posiphen; Posiphen Tartrate

Latest Information Update: 22 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institute on Aging; National Institutes of Health (USA); Raptor Pharmaceutical Corp
  • Developer Annovis Bio; Cenomed BioSciences; Rockefeller University; University of California at Los Angeles
  • Class Antidementias; Antidotes; Antiparkinsonians; Nootropics; Phenylcarbamates; Small molecules; Vascular disorder therapies
  • Mechanism of Action Acetylcholinesterase inhibitors; Alpha-synuclein inhibitors; Amyloid beta-protein precursor inhibitors; Huntingtin protein inhibitors; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease; Parkinson's disease
  • Phase II Lewy body disease; Mild cognitive impairment
  • Phase I Down syndrome
  • No development reported Frontotemporal dementia; Huntington's disease; Poisoning; Stroke; Traumatic brain injuries

Most Recent Events

  • 09 Jan 2026 Phase-II/III clinical trials in Parkinson's disease (Treatment-experienced, In the elderly, In adults) in USA (PO) (NCT07284784)
  • 19 Dec 2025 Annovis Bio announces intention to submit NDA to US FDA for Parkinson's disease
  • 16 Dec 2025 Annovis Bio plans a phase II/III trial for Parkinson's disease in USA (PO, Capsules) in January 2026 (NCT07284784)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top